ACUR : Summary for Acura Pharmaceuticals, Inc. - Yahoo Finance

U.S. Markets open in 3 hrs 22 mins

Acura Pharmaceuticals, Inc. (ACUR)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.92-0.02 (-2.12%)
At close: 4:00 PM EST
People also watch:
ABIOAEZSALIMAPRIAPPY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close0.94
Open0.00
Bid0.70 x 100
Ask0.96 x 900
Day's Range0.90 - 0.96
52 Week Range0.85 - 3.52
Volume26,057
Avg. Volume47,373
Market Cap10.89M
Beta2.24
PE Ratio (TTM)-1.11
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Capital Cube2 days ago

    ETFs with exposure to Acura Pharmaceuticals, Inc. : December 7, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to Acura Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to ACUR-US. Comparing the performance and risk of Acura Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Acura Pharmaceuticals, Inc. :ACUR-US: Earnings Analysis: Q3, 2016 By the Numbers : November 18, 2016
    Capital Cube21 days ago

    Acura Pharmaceuticals, Inc. :ACUR-US: Earnings Analysis: Q3, 2016 By the Numbers : November 18, 2016

    Categories: Yahoo Finance Get free summary analysis Acura Pharmaceuticals, Inc. reports financial results for the quarter ended September 30, 2016. We analyze the earnings along side the following peers of Acura Pharmaceuticals, Inc. – Elite Pharmaceuticals, Inc., Windtree Therapeutics, Inc., Innoviva, Inc., Aradigm Corporation, Johnson & Johnson, OPKO Health, Inc., Pfizer Inc., Nektar Therapeutics, Rigel Pharmaceuticals, Inc. and ... Read more (Read more...)

  • Marketwired25 days ago

    Acura Pharmaceuticals Announces Third Quarter 2016 Financial Results

    Acura Pharmaceuticals, Inc. , a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three and nine months ended September 30, 2016. The Company ...